1. Hong Kong Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Prenetics Global Limited

Prenetics Global Limited

PRENW
Prenetics Global LimitedUS flagNASDAQ Global Market
0.02
USD
+0.00
- -
224,827.00Market Cap
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
9
65
13
13
6
16
92
95
Operating Margin (%)
-197.44
1.48
-450.43
-500.74
-689.99
-240.19
-41.27
-42.59
Depreciation Expense
2
2
7
8
8
6
4
- -
Net Income, GAAP
-20
-2
-174
-190
-63
-46
-38
-38
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-218.15
-2.98
-1,388.44
-1,446.78
-1,019.07
-290.56
-40.82
-39.65
Working Capital
- -
-3
48
185
54
50
56
56
LT Debt
- -
1
4
4
1
3
- -
- -
Total Equity
- -
31
-401
243
210
171
156
156
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-7.29
-653.65
- -
- -
- -
- -
-736,906.97

Capital Structure

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
ST Debt
2
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
13
14
17
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
Total Current Assets
99
90
85
Cash, Cash Equivalents & STI
28
24
63
Accounts Receivable, Net
2
2
3
Inventories
4
5
7
Total Current Liabilities
46
34
29
Payables & Accruals
14
17
24
ST Debt
2
1
1
Deferred Revenue
7
7
3

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-318.91%
-8.74%
Free Cash Flow
- -
30.71%
155.15%
Net Income, GAAP
- -
1,753.73%
-18.56%
Sales/Revenue/Turnover
- -
101.94%
479.76%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
5
7
5
5
6
2024
6
15
4
10
16
2025
17
18
24
37
92

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Sheng Wu Yeung
Full Time Employees
285
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Address
Unit 701-706, K11 Atelier King’s Road Quarry Bay Hong Kong
IPO Date
Jul 16, 2021
CIK
0001876431
Website
prenetics.com
Similar Companies
LungLife AI, Inc. (LLAI.L)
Abingdon Health Plc (ABDX.L)
Hangzhou Tigermed Consulting Co., Ltd. (300347.SZ)
Invitae Corporation (NVTAQ)
MDxHealth S.A. (MXDHF)
Lonza Group AG (LZAGF)
Business
Prenetics Global Limited (PRENW) is a health sciences company focused on advancing consumer health through genomics-driven diagnostics, prevention services and wellness products in Hong Kong, the United States, Taiwan and internationally. Founded in 2014 and headquartered in Quarry Bay, Hong Kong, the company operates three main segments: Prevention, offering CircleDNA consumer genetic testing using next-generation sequencing for health, wellness and predisposition insights including nutrigenomics and pharmacogenomics; Diagnostics, providing precision oncology services through ACT Genomics such as ACTOnco comprehensive cancer tests for solid tumors, ACTHRD for homologous recombination deficiency and genomic profiling panels; and Consumer Health, selling premium supplements and wellness products under the IM8 brand alongside fulfillment and distribution of sports nutrition via the Europa Sports Partners brand. Prenetics recently acquired Europa Sports Partners and its subsidiary Hubmatrix in 2024 to expand into the US consumer health and wellness market projecting over $100 million in consumer segment revenue by fiscal 2025, launched IM8 as a flagship health brand in collaboration with figures like David Beckham, established the first consumer health company Bitcoin treasury with a strategic accumulation including 100 Bitcoin acquired in 2025 at an average $109,594 per coin, and saw executives announce open-market share purchases totaling approximately $1.45 million in November 2025. The company targets individual consumers, clinicians and athletes across biotechnology, health sciences and consumer health sectors with subsidiaries including ACT Genomics and IM8 Health.